Theravance Biopharma (TBPH) Retained Earnings (2014 - 2026)
Theravance Biopharma's (TBPH) quarterly Retained Earnings came in at -$62000.0 in Q1 2026, down 100.01% year-on-year from $1.1 billion in Q1 2025, and down 100.01% on a QoQ basis from $1.2 billion in Q4 2025.
Theravance Biopharma (TBPH) Retained Earnings (2014 - 2026) Analysis & Trends
Theravance Biopharma (TBPH) has 13 years of Retained Earnings data on file, last reported at -$62000.0 in Q1 2026.
- On a quarterly basis, Retained Earnings fell 100.01% year-over-year to -$62000.0 in Q1 2026; TTM through Mar 2026 was -$62000.0, a 100.01% decrease from a year earlier, with the FY2025 full-year figure at $1.2 billion, up 219.76% from the prior year.
- Retained Earnings for Q1 2026 stood at -$62000.0, down from $1.2 billion in the prior quarter.
- Over the last five years, Retained Earnings for TBPH reached as high as $1.3 billion in Q4 2022 and fell as low as -$1.8 billion in Q2 2022.
- Historically, Retained Earnings has averaged $64.7 million across 5 years, with a median of -$22000.0 in 2024.
- Across the five-year window, Retained Earnings tumbled 22002350.0% in 2022 and jumped 235.97% in 2023, its largest moves.
- Year by year, Retained Earnings stood at $1.3 billion in 2022, then sank by 170.16% to -$909.1 million in 2023, then decreased by 6.21% to -$965.5 million in 2024, then jumped by 219.76% to $1.2 billion in 2025, then slumped by 100.01% to -$62000.0 in 2026.
- Per Business Quant data, the three most recent Retained Earnings figures were -$62000.0 in Q1 2026, $1.2 billion in Q4 2025, and -$920.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -527.87 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | -27.89 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 12.91 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 115.82 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 14.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 11.90 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -622,000.00 |
| 10 | Theravance Biopharma | 864.56 Mn | 469.90 Mn | - | -62,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -62,000.00 |
| Dec 31, 2025 | 1.16 Bn |
| Sep 30, 2025 | -920.65 Mn |
| Jun 30, 2025 | -10,000.00 |
| Mar 31, 2025 | 1.15 Bn |
| Dec 31, 2024 | -965.52 Mn |
| Sep 30, 2024 | 1.14 Bn |
| Jun 30, 2024 | -22,000.00 |
| Mar 31, 2024 | 1.13 Bn |
| Dec 31, 2023 | -909.10 Mn |
| Sep 30, 2023 | 1.15 Bn |
| Jun 30, 2023 | -286,000.00 |
| Mar 31, 2023 | 1.25 Bn |
| Dec 31, 2022 | 1.30 Bn |
| Sep 30, 2022 | -843.55 Mn |
| Jun 30, 2022 | -1.76 Bn |
| Mar 31, 2022 | -1.75 Bn |
| Dec 31, 2021 | -1.73 Bn |
| Sep 30, 2021 | 14,000.00 |
| Jun 30, 2021 | 8,000.00 |